Patients with obesity were less likely to receive the antiplatelet medication ticlopidine/clopidogrel but were more likely to receive an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, calcium channel blockers, and long-acting nitrates. The gene discussed is ACE; the disease is obesity disorder.